New cancer clinical trial: Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Published on: March 19, 2018 at 12:00PM
Conditions:   c-MET Gene Amplification;   MET Exon 14 Mutation;   Metastatic Non-Squamous Non-Small Cell Lung Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   RET/PTC Rearrangement;   ROS1 Gene Rearrangement;   Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
Sponsor:   National Cancer Institute (NCI)
Recruiting
http://ift.tt/2pqL9By